ACADIA Pharmaceuticals Inc. $ACAD Shares Purchased by Voya Investment Management LLC

Voya Investment Management LLC increased its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 70.3% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 61,585 shares of the biopharmaceutical company's stock after purchasing an additional 25,418 shares during the quarter. Voya Investment Management LLC's holdings in ACADIA Pharmaceuticals were worth $1,023,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Vanguard Group Inc. increased its position in shares of ACADIA Pharmaceuticals by 9.0% during the 1st quarter. Vanguard Group Inc. now owns 15,203,234 shares of the biopharmaceutical company's stock worth $252,526,000 after purchasing an additional 1,255,594 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of ACADIA Pharmaceuticals during the 1st quarter worth about $60,845,000. Fred Alger Management LLC increased its position in shares of ACADIA Pharmaceuticals by 2.0% during the 1st quarter. Fred Alger Management LLC now owns 2,769,828 shares of the biopharmaceutical company's stock worth $46,007,000 after purchasing an additional 54,899 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its position in shares of ACADIA Pharmaceuticals by 73.7% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,977,432 shares of the biopharmaceutical company's stock worth $32,845,000 after purchasing an additional 838,728 shares during the last quarter. Finally, American Century Companies Inc. increased its position in shares of ACADIA Pharmaceuticals by 1,055.8% during the 1st quarter. American Century Companies Inc. now owns 1,632,749 shares of the biopharmaceutical company's stock worth $27,120,000 after purchasing an additional 1,491,484 shares during the last quarter. 96.71% of the stock is owned by institutional investors and hedge funds.

ACADIA Pharmaceuticals Stock Down 3.8%

ACAD stock opened at $23.60 on Wednesday. The business has a 50 day moving average price of $24.39 and a 200 day moving average price of $20.62. The stock has a market cap of $3.98 billion, a price-to-earnings ratio of 17.74, a PEG ratio of 6.21 and a beta of 0.75. ACADIA Pharmaceuticals Inc. has a fifty-two week low of $13.40 and a fifty-two week high of $26.65.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.16 earnings per share for the quarter, beating analysts' consensus estimates of $0.14 by $0.02. ACADIA Pharmaceuticals had a return on equity of 14.69% and a net margin of 21.80%.The company had revenue of $264.57 million during the quarter, compared to analysts' expectations of $263.07 million. During the same quarter in the previous year, the business earned $0.20 earnings per share. The firm's revenue for the quarter was up 9.4% on a year-over-year basis. As a group, sell-side analysts anticipate that ACADIA Pharmaceuticals Inc. will post 0.7 EPS for the current year.

Insider Buying and Selling

In other ACADIA Pharmaceuticals news, Director Elizabeth A. Garofalo sold 1,600 shares of the business's stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $25.98, for a total value of $41,568.00. Following the completion of the sale, the director owned 25,382 shares in the company, valued at approximately $659,424.36. The trade was a 5.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Mark C. Schneyer sold 3,498 shares of the business's stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $23.65, for a total value of $82,727.70. Following the completion of the sale, the executive vice president owned 43,447 shares of the company's stock, valued at approximately $1,027,521.55. This represents a 7.45% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 27,098 shares of company stock valued at $678,256. 28.30% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on ACAD shares. JMP Securities raised their price objective on ACADIA Pharmaceuticals from $37.00 to $38.00 and gave the stock a "market outperform" rating in a research report on Thursday, August 7th. Oppenheimer restated a "market perform" rating and set a $22.00 target price (up from $19.00) on shares of ACADIA Pharmaceuticals in a report on Thursday, June 26th. Cowen restated a "buy" rating on shares of ACADIA Pharmaceuticals in a report on Thursday, September 11th. Needham & Company LLC restated a "buy" rating and set a $30.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday, June 26th. Finally, TD Cowen raised their target price on ACADIA Pharmaceuticals from $35.00 to $39.00 and gave the company a "buy" rating in a report on Thursday, September 11th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, ACADIA Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $29.65.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.